The push to shore up IP issues here in SA is seemingly gaining some momentum.
The lobbying aside, there is probably a bit of fear. Every government knows they need the meds, and there must be some fear, ( and probably threats)that if we piss the drug guys off they will say, ok, we won't make that, or we will limit that. The people will turn against government and not the company.
recouping costs, the developer still has certain advantages even if patent period is shortened. They can release their drug into the market as a generic 2/3 years before the patent expires, thus establishing a foothold, and obviously they have a zero development cost which means they can enter at a power price.
On a separate, yet linked issue, is actual pricing. If you see the price through medical aids and compare it to across the counter, the price is huge. Across the counter the meds may be R600, yet dispensed via a medical aid (the customer), it may be R400, as an example.
Having thought of this, perhaps the pricing structures is the thing to look at.
The lobbying aside, there is probably a bit of fear. Every government knows they need the meds, and there must be some fear, ( and probably threats)that if we piss the drug guys off they will say, ok, we won't make that, or we will limit that. The people will turn against government and not the company.
recouping costs, the developer still has certain advantages even if patent period is shortened. They can release their drug into the market as a generic 2/3 years before the patent expires, thus establishing a foothold, and obviously they have a zero development cost which means they can enter at a power price.
On a separate, yet linked issue, is actual pricing. If you see the price through medical aids and compare it to across the counter, the price is huge. Across the counter the meds may be R600, yet dispensed via a medical aid (the customer), it may be R400, as an example.
Having thought of this, perhaps the pricing structures is the thing to look at.
Comment